Indication

For the adjunctive treatment of focal onset seizures (FOS) with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite treatment with at least two anti-epileptic products.

Medicine details

Medicine name:
cenobamate (Ontozry)
SMC ID:
SMC2408
Pharmaceutical company
Arvelle Therapeutics, A Angelini Pharma Group Company
BNF chapter
Central nervous system
Submission type
Full
Publication due date:
07 February 2022
SMC meeting date:
11 January 2022
Patient group submission deadline:
29 November 2021